Development and validation of a grading system for the quality of cost-effectiveness studies

被引:274
作者
Chiou, CF
Hay, JW
Wallace, JF
Bloom, BS
Neumann, PJ
Sullivan, SD
Yu, HT
Keeler, EB
Henning, JM
Ofman, JJ
机构
[1] Zynx Hlth Inc, Cedars Sinai Hlth Syst, Beverly Hills, CA 90212 USA
[2] Univ So Calif, Dept Pharmaceut Econ & Policy, Los Angeles, CA USA
[3] Univ Penn, Dept Med, Inst Aging, Philadelphia, PA 19104 USA
[4] Univ Penn, Leonard Davis Inst Hlth Econ, Inst Aging, Philadelphia, PA 19104 USA
[5] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[6] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[7] RAND Corp, Santa Monica, CA USA
[8] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
[9] Cedars Sinai Hlth Syst, Dept Med & Hlth Serv Res, Los Angeles, CA USA
关键词
cost-effectiveness; quality assessment; conjoint analysis; convergent validity;
D O I
10.1097/00005650-200301000-00007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
PURPOSE. To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies. METHODS. A committee comprised of health economists selected a set of criteria for the instrument from an item pool. Data collected with a conjoint analysis survey on 120 international health economists were used to estimate weights for each criterion with a random effects regression model. To validate the grading system, a survey was sent to 60 individuals with health economics expertise. Participants first rated the quality of three CE studies on a visual analogue scale, and then evaluated each study using the grading system. Spearman rho and Wilcoxon tests were used to detect convergent validity and analysis of covariance (ANCOVA) for discriminant validity. Agreement between the global rating by experts and the grading system was also examined. RESULTS. Sixteen criteria were selected. Their coefficient estimates ranged from 1.2 to 8.9, with a sum of 93.5 on a 100-point scale. The only insignificant criterion was "use of subgroup analyses." Both convergent validity and discriminant validity of the grading system were shown by the results of the Spearman rho (correlation coefficient = 0.78, P <0.0001), Wilcoxon test (P = 0.53), and ANCOVA (F-3,F-146 = 5.97, P = 0.001). The grading system had good agreement with global rating by experts. CONCLUSIONS. The instrument appears to be simple, internally consistent, and valid for measuring the perceived quality of CE studies. Applicability for use in clinical and resource allocation decision-making deserves further study.
引用
收藏
页码:32 / 44
页数:13
相关论文
共 36 条
[1]
ECONOMIC-ANALYSIS IN RANDOMIZED CONTROL TRIALS [J].
ADAMS, ME ;
MCCALL, NT ;
GRAY, DT ;
ORZA, MJ ;
CHALMERS, TC .
MEDICAL CARE, 1992, 30 (03) :231-243
[2]
The Danish approach to standards for economic evaluation methodologies [J].
Alban, A ;
Gyldmark, M ;
Pedersen, AV ;
Sogaard, J .
PHARMACOECONOMICS, 1997, 12 (06) :627-636
[3]
Baladi JF, 1998, HEALTH ECON, V7, P221, DOI 10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO
[4]
2-N
[5]
COMPARING 2 METHODS OF CLINICAL MEASUREMENT - A PERSONAL HISTORY [J].
BLAND, JM ;
ALTMAN, DG .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 :S7-S14
[6]
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[7]
Common errors and controversies in pharmacoeconomic analyses [J].
Byford, S ;
Palmer, S .
PHARMACOECONOMICS, 1998, 13 (06) :659-666
[8]
*CAN COORD OFF HLT, 1997, GUID EC EV PHARM
[9]
METHODOLOGICAL AND CONDUCT PRINCIPLES FOR PHARMACOECONOMIC RESEARCH [J].
CLEMENS, K ;
TOWNSEND, R ;
LUSCOMBE, F ;
MAUSKOPF, J ;
OSTERHAUS, J ;
BOBULA, J .
PHARMACOECONOMICS, 1995, 8 (02) :169-174
[10]
*COM DEP HLTH HACS, 1995, GUID PHARM IND PREP